ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Current patterns of next-generation sequencing testing in biliary tract cancer patients in Spain.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBiliary tract cancer (BTC), which includes cholangiocarcinoma (CCA) and gallbladder cancer (GBC), presents high levels of molecular heterogeneity and a poor prognosis. Next-generation sequencing (NGS) is crucial for identifying genomic alterations and adequate targeted therapies, but its integration into clinical practice varies by region. This study assesses how NGS is implemented in Spain, focusing on its use, barriers, and clinical impact on managing BTC.
methodsThis study was based on a national survey of healthcare professionals involved in the diagnosis and treatment of BTC.
resultsSeventy-six experts participated in the general analysis, and 58 participated in the BTC-specific analysis. Among the respondents, 95% reported access to NGS in oncology practice, and 93% reported its use in BTC. FGFR2 and IDH1/2 were the most frequently requested biomarkers (both 91%), whereas TMB (22%) and expanded panels were less commonly used. Thirty-two of 50 respondents requested NGS in advanced disease (64%), as per the responses to this specific question, which is consistent with current therapeutic indications. Thirty-four of 48 respondents performing NGS (71%) reported access to specialized genetic counseling. The perceived therapeutic impact varied: many estimated that NGS influenced treatment decisions in 20-40% of cases, whereas a subset reported that it influenced treatment decisions in more than 60% of cases.
conclusionsThe adoption of NGS in BTC management in Spain has increased alongside the availability of targeted therapies. The respondents reported broad access to NGS and frequent use of key biomarkers, mainly in advanced disease. Variability in biomarker selection, timing, and access to counseling reflects differences in local practice. Initiatives that support harmonized diagnostic pathways may further strengthen precision oncology in BTC.
Indexed as
Identifiers
42207430What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.